- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02575066
Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients (PASART-2)
Phase II Clinical Study of Concurrent Pazopanib for Non-metastatic Sarcoma Patients to be Treated With Radiotherapy, Localized in the Extremities, Trunk and Chest Wall or the Head and Neck Region (PASART-2)
Radiotherapy (RT) alone is able to induce a clinically significant effect with a variable pathologic response (a pathological complete remission, pCR, defined as ≥ 95%, or ≤ 5% remaining visible tumour cells) in only about 10% of cases. A prior phase I study (PASART-1; NCT01985295) suggested that 25 x 2 Gy preoperative RT in combination with once daily 800mg oral pazopanib is feasible, while inducing tissue replacing tumor that can consist of fibrosis and necrosis in 40% of thus treated patients.
During this study, the interim analysis showed that the combination treatment of preoperative radiation with orally pazopanib is more effective than was anticipated. For this reason, the pazopanib dose of 800 mg once daily is maintained but the RT dose is reduced to 18x2Gy instead of 25x2Gy. Predominant aim of this RT dose reduction is lowering the wound complication risk after preoperative radiotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients of the first part of the study received radiotherapy (25x2Gy) and pazopanib (QD 800 mg).
Patients of the second part of the study received/ will receive radiotherapy (18x2Gy) and pazopanib (QD 800 mg).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands, 1066CX
- Antoni van Leeuwenhoek
-
Leiden, Netherlands, 2333 ZA
- Leids Universitair Medisch Centrum
-
-
-
-
-
London, United Kingdom, SW3 6JJ
- Royal Marsden Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed newly diagnosed intermediate to high grade soft tissue sarcoma localized to the extremities, trunk and chest wall or the head and neck area, for which the standard treatment is a combination of and radiotherapy and surgery(deep seated and/or > 5cm according to the RECIST 1.1 criteria and/or an anticipated close resection margin and/or grade II/III according to the WHO definition)
- Age ≥ 18 years
- WHO performance status of ≤ 1
- Able and willing to undergo blood sampling for PK and PD analysis
- Able to swallow and retain oral medication
- Able and willing to undergo MRI scanning
- Able and willing to undergo tumor biopsies
- Adequate organ functions as described by the laboratory findings in the table 1. For thyroid function, the T4 and TSH values must be within normal values of the range of the participating centers
- Written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up.
Exclusion Criteria
- Prior malignancies; except another malignancy and disease-free for ≥ 5 years, or completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma.
- Patients with recurrent sarcomas (even without prior radiotherapy)
- Ewing sarcoma and other PNET family tumors, rhabdomyosarcomas (both pediatric and adult), osteosarcomas
- Clinically significant gastrointestinal abnormalities which might interfere with oral dosing diagnosed
- Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg]
- Unstable or serious concurrent condition (e.g., active infection requiring systemic therapy)
- Prolongation of corrected QT interval (QTc) > 480 msecs on ECG
- History of any of more of the following cardiovascular conditions within the past 6 months:
- Cardiac angioplasty or stenting
- Myocardial infarction
- Unstable angina
- Symptomatic peripheral vascular disease
- Coronary artery by-pass graft surgery
- Class II, III or IV congestive heart failure as defined by the New York Heart Association (NYHA)
- History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
- Macroscopic hematuria
- Hemoptysis that is clinically relevant within 4 weeks of first dose of pazopanib
- Evidence of active bleeding or bleeding diathesis
- Prior major surgery or trauma within 28 days prior to first dose of study medication and/or presence of any non-healing wound, fracture, or ulcer
- Chemotherapy or radiation therapy within 2 weeks prior to the first dose of study medication
- Biological therapy or treatment with an investigational agent within 28 days or five half-lives, whichever is longer prior to the first dose of study medication
- Prohibited medications listed in the protocol for 14 days or five half-lives of a drug (whichever is longer) prior to visit 1 and for the duration of the study
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: radiotherapy combined with pazopanib
patients during the first part of the study received concurrent radiotherapy (25x2Gy) and pazopanib (QD 800 mg).
The patients of the second part of the study will receive concurrent radiotherapy (18x2Gy) and pazopanib (QD 800 mg).
|
external beam radiotherapy 25 x 2 Gy / 18 x 2 Gy
Other Names:
pazopanib QD 800 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pathological near complete remission of the resected specimen which has been treated with radiotherapy
Time Frame: 6 weeks post treatment
|
Proportion of patients with resection specimens demonstrating induction of a pathological (near) complete remission (≥ 95% tumor regression).
Pathological (near) complete remission is defined as ≥ 95% replacement of tumor with other tissue, usually fibrosis and) in the resection specimen post combined pazopanib and radiotherapy treatment
|
6 weeks post treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence toxicities measured by NCI-CTCAE v4.0 (radiotherapy alone, pazopanib alone or both) measured from start of treatment until 6 weeks post-treatment
Time Frame: during treatment and up to 6 weeks post treatment
|
during treatment and up to 6 weeks post treatment
|
Rate of response as measured by RECIST v 1.1 at 4 weeks after completing radiotherapy
Time Frame: 4 weeks post treatment
|
4 weeks post treatment
|
Incidence of acute post-operative wound complications up to 3 weeks (+/- 1 week) after surgery as defined in section 6.1.3 and reference 29 (see also appendix XII)
Time Frame: up to 3 weeks post surgery
|
up to 3 weeks post surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M15PAS
- DSSG02 (Other Identifier: Dutch Sarcoma Study Group)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
Centre Oscar LambretFrench Sarcoma Group; Study Group of Bone TumorsCompletedSoft Tissue Sarcoma | Uterine SarcomaFrance
-
Advenchen Laboratories, LLCActive, not recruitingLeiomyosarcoma | Synovial Sarcoma | Alveolar Soft Part Sarcoma | Soft-Tissue SarcomaUnited States, United Kingdom, Spain, China, Italy
Clinical Trials on external beam radiotherapy
-
Peking University Third HospitalNot yet recruitingEndometrial Cancer | Radiotherapy | PathologyChina
-
University of StellenboschUnknown
-
University Hospital MuensterDeutsche Krebshilfe e.V., Bonn (Germany)Completed
-
Rigshospitalet, DenmarkDanish Center for Interventional Research in Radiation Oncology (CIRRO)Terminated
-
AHS Cancer Control AlbertaCross Cancer InstituteCompletedCarcinoma, Small CellCanada
-
National Cancer Center, KoreaCompleted
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompleted
-
Lithuanian University of Health SciencesUnknownMultiple Myeloma and Malignant Plasma Cell NeoplasmsLithuania
-
Heidelberg UniversityCompletedNeurological Outcome | Survival From First Diagnosis Metastatic Spinal Cord Compression to DeathGermany
-
International Atomic Energy AgencyTata Memorial Centre; University of Maryland, College Park; Centro de Lucha contra... and other collaboratorsUnknownSquamous Cell Carcinoma of the Head and NeckIndia, Argentina, Cuba, Indonesia, Pakistan, Philippines, South Africa, Thailand, Uruguay